Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 3/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6728898 | 0.92 | GRIK1 (0.58) | GRIK1RXFP1MAPTALDH1A1GAA | |
| SCHEMBL6719306 | 0.86 | RXFP1 (0.46) | GRIK1RXFP1MAPTALDH1A1GAA | |
| SCHEMBL6719194 | 0.86 | THRB (0.47) | GRIK1RXFP1MAPTALDH1A1GAA | |
| SCHEMBL6727476 | 0.86 | PTGER3 (0.48) | GRIK1RXFP1MAPTALDH1A1GAA | |
| SCHEMBL6720730 | 0.86 | ALDH1A1 (0.47) | GRIK1RXFP1MAPTALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL7204817 | 0.85 | SIGMAR1 (0.48) | GRIK1RXFP1MAPTALDH1A1GAA | |
| SCHEMBL2288364 | 0.85 | MAPT (0.64) | MAPTALDH1A1GAANPSR1TDP1 | |
| SCHEMBL6724643 | 0.84 | LMNA (0.42) | GRIK1RXFP1MAPTALDH1A1GAA | |
| SCHEMBL6716936 | 0.81 | TAS2R14 (0.48) | RXFP1MAPTGAANPSR1MEN1 | |
| Hydrochloric Acid SCHEMBL7203936 | 0.80 | TAS2R14 (0.47) | RXFP1MAPTGAANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137784-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-09-26 | — | — | US | claimed |
| US-20020049246-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-04-25 | — | — | US | claimed |
| EP-1091942-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-04-18 | — | — | EP | claimed |
| WO-2000001676-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2000-01-13 | — | — | WO | claimed |
| US-6569880-B2 | Guanidine derivatives | NEUROSEARCH A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| US-20020137784-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-09-26 | — | — | US | disclosed |
| US-6380180-B1 | BENZIMIDAZOLE COMPOUNDS FOR TREATMENT OF ASTHMA, VASOSPASM, MEMORY LOSS, MIGRAINE AND OTHERS DISEASES ASSOCIATED WITH POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20020049246-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-04-25 | — | — | US | disclosed |
| EP-1091942-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-04-18 | — | — | EP | disclosed |
| US-6194447-B1 | ASTHMA, ANTICONVULSANTS, COGNITION ACTIVATORS, BRAIN DISORDERS, PSYCHOLOGICAL DISORDERS, CARDIOVASCULAR DISORDERS,GASTROINTESTINAL DISORDERS | NEUROSEARCH A/S (DK) | 2001-02-27 | — | — | US | disclosed |
| WO-2000001676-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137784-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | GRIK1 112/4885RXFP1 591/4885MAPT 918/4885 |
| US-20020049246-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | GRIK1 112/4885RXFP1 591/4885MAPT 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.